Dolby Laboratories (DLB) Projected to Post Quarterly Earnings on Thursday

Dolby Laboratories (NYSE:DLB - Get Free Report) is projected to announce its Q3 2025 earnings results after the market closes on Thursday, July 31st. Analysts expect Dolby Laboratories to post earnings of $0.72 per share and revenue of $305.23 million for the quarter. Dolby Laboratories has set its FY 2025 guidance at 3.880-4.030 EPS and its Q3 2025 guidance at 0.620-0.770 EPS.

Dolby Laboratories (NYSE:DLB - Get Free Report) last announced its earnings results on Thursday, May 1st. The electronics maker reported $1.34 EPS for the quarter, beating the consensus estimate of $1.29 by $0.05. The business had revenue of $369.56 million for the quarter, compared to the consensus estimate of $375.44 million. Dolby Laboratories had a return on equity of 11.48% and a net margin of 19.44%. The company's revenue was up 1.4% on a year-over-year basis. During the same period last year, the business posted $1.27 EPS. On average, analysts expect Dolby Laboratories to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Dolby Laboratories Price Performance

DLB traded down $0.01 during trading on Friday, hitting $76.32. The company had a trading volume of 209,957 shares, compared to its average volume of 310,830. Dolby Laboratories has a 1-year low of $66.35 and a 1-year high of $89.66. The business has a 50-day moving average of $75.04 and a 200-day moving average of $77.70. The company has a market cap of $7.33 billion, a PE ratio of 28.80 and a beta of 0.91.

Dolby Laboratories Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, May 21st. Investors of record on Tuesday, May 13th were paid a dividend of $0.33 per share. The ex-dividend date of this dividend was Tuesday, May 13th. This represents a $1.32 dividend on an annualized basis and a yield of 1.73%. Dolby Laboratories's payout ratio is currently 49.81%.

Wall Street Analyst Weigh In

Several equities analysts have commented on DLB shares. Tigress Financial started coverage on shares of Dolby Laboratories in a research note on Thursday, May 15th. They set a "buy" rating and a $112.00 target price on the stock. Wall Street Zen upgraded Dolby Laboratories from a "hold" rating to a "buy" rating in a research report on Friday, May 30th. Rosenblatt Securities reiterated a "buy" rating and issued a $95.00 target price on shares of Dolby Laboratories in a report on Friday, June 13th. Finally, Barrington Research reaffirmed an "outperform" rating and set a $100.00 target price on shares of Dolby Laboratories in a report on Friday, May 2nd.

Insiders Place Their Bets

In related news, SVP John D. Couling sold 675 shares of the firm's stock in a transaction on Monday, May 5th. The stock was sold at an average price of $75.04, for a total value of $50,652.00. Following the completion of the transaction, the senior vice president directly owned 121,151 shares of the company's stock, valued at $9,091,171.04. This trade represents a 0.55% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Mark Andrew Sherman sold 15,000 shares of the stock in a transaction on Wednesday, June 4th. The shares were sold at an average price of $75.02, for a total transaction of $1,125,300.00. Following the completion of the transaction, the executive vice president owned 62,397 shares of the company's stock, valued at approximately $4,681,022.94. This represents a 19.38% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 116,724 shares of company stock worth $8,764,043 in the last ninety days. Insiders own 38.39% of the company's stock.

Institutional Investors Weigh In On Dolby Laboratories

A number of institutional investors have recently added to or reduced their stakes in the stock. Focus Partners Wealth bought a new stake in Dolby Laboratories during the first quarter worth about $390,000. Royal Bank of Canada lifted its position in shares of Dolby Laboratories by 3.5% during the first quarter. Royal Bank of Canada now owns 68,367 shares of the electronics maker's stock worth $5,491,000 after purchasing an additional 2,298 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in Dolby Laboratories by 5.6% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 238,216 shares of the electronics maker's stock valued at $19,131,000 after buying an additional 12,598 shares during the last quarter. Finally, Goldman Sachs Group Inc. increased its stake in shares of Dolby Laboratories by 218.8% in the 1st quarter. Goldman Sachs Group Inc. now owns 249,574 shares of the electronics maker's stock valued at $20,043,000 after buying an additional 171,288 shares during the period. 58.56% of the stock is owned by institutional investors and hedge funds.

Dolby Laboratories Company Profile

Dolby Laboratories, Inc creates audio and imaging technologies that transform entertainment at the cinema, DTV transmissions and devices, mobile devices, OTT video and music services, home entertainment devices, and automobiles. The company develops and licenses its audio technologies, such as AAC & HE-AAC, a digital audio codec solution used for a range of media applications; AVC, a digital video codec with high bandwidth efficiency used in various media devices; Dolby AC-4, a digital audio coding technology that delivers new audio experiences to a range of playback devices; and Dolby Atmos technology for cinema and various media devices.